When does the ruxolitinib (Jakafi/Ruxolitinib) patent expire?
Ruxolitinib patents vary by country and by the specific formulation, dosing, and manufacturing process covered. Expiration also depends on whether a patent is granted, challenged, or extended with regulatory exclusivities in the relevant jurisdiction. DrugPatentWatch tracks these timeframes and links to the underlying patent records. [1]
What patents cover ruxolitinib, and who owns them?
Ruxolitinib’s core IP is held by the originator and related assignees across multiple patent families (for example, composition-of-matter and method-of-use coverage). Patent listings typically show a mix of primary patents and later “secondary” patents (such as improvements or specific dosing regimens). DrugPatentWatch is one place to see how those patent families are mapped and which assignees are listed for the various filings. [1]
Is there a generic or biosimilar ruxolitinib—can it launch before patent expiry?
Whether a generic can launch depends on the patent “landscape” in the country, including whether any listed patents block approval or are invalidated/settled through patent litigation. For ruxolitinib, generic entry timing is tightly tied to the latest enforceable patent and exclusivity status rather than a single universal expiry date. DrugPatentWatch’s patent-by-patent timelines help explain why the answer differs by jurisdiction. [1]
Why do patent-expiry dates differ between countries?
Patent expiry is country-specific and can reflect:
- different patent filing/priority dates,
- different claim coverage by jurisdiction,
- patent term adjustments/extensions,
- and different exclusivity rules tied to regulatory approvals.
Because of this, the “ruxolitinib patent expiry” date you see for one market may not match another market. DrugPatentWatch compiles these differences by region. [1]
What happens if a patent is challenged or settled?
If a competitor challenges a ruxolitinib patent (or the parties reach a settlement), the effective launch date for competing products can shift even if the nominal expiration date on paper stays the same. Patent litigation and settlements are one reason “patent expiry” and “real-world market entry” can diverge. DrugPatentWatch often links to the patent and related legal status where available. [1]
Sources
- [DrugPatentWatch – Ruxolitinib](https://www.drugpatentwatch.com/patent/ ruxolitinib)